However, when treated with ipilimumab and PD-1, prostate cancer cells in the bone bypassed drug-induced immune attacks, presenting with upregulated bone destruction driven by TGF-β-induced tumor cell growth while also blocking activated T cells’ effects [198]. This evidence concerns the gene TGFB1 and prostate cancer.